GeneNews expands availability of ColonSentry(TM) in Southwestern Ontario

             - ColonSentry(TM) now available in London, Ontario -

TORONTO, Feb. 19 /CNW/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has expanded access to its ColonSentry(TM) test, the world's first blood-based test to determine a person's current risk for colorectal cancer, into Southwestern Ontario. Gamma-Dynacare Medical Laboratories, a leading provider of laboratory services, information and products in Canada, will provide blood specimen collection services for ColonSentry(TM) from three of its Patient Service Centres in London, Ontario.

"Expanding the availability of ColonSentry into additional regions of Southwestern Ontario, beginning with London, will further drive the adoption of our unique test. Gamma-Dynacare is one of Canada's largest and most respected providers of medical laboratory services and we are pleased that our partnership has broadened from their Toronto-area centres into this new region," said Gailina Liew, Chief Operating Officer of GeneNews. "In addition to the 1.5 million eligible adults for our ColonSentry test in the Greater Toronto Area, there are another 488,000 people aged 50-79 in Southwestern Ontario who are potential candidates for this colorectal cancer blood test."

Gamma-Dynacare is currently offering specimen collection services for the ColonSentry(TM) test at ten locations in the Greater Toronto Area and at the following location in London, Ontario:

    245 Pall Mall Street
    London, Ontario
    N6A 1P4

Two additional sites in the London area will become available in March. More information about the ColonSentry test and specimen collection sites can be found at

    About Gamma-Dynacare Medical Laboratories

Gamma-Dynacare is one of Canada's largest and most respected providers of laboratory services and solutions. Our skilled and dedicated employees perform millions of tests each year in our state-of-the-art facilities, playing a key role in the treatment of patients and the prevention and diagnosis of disease. By living our mission of "Caring for People", we positively impact the health and wellness of people across Canada and are a valuable contributor to the betterment of the overall healthcare system. For additional information please visit

    About GeneNews

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE GeneNews Limited

For further information: For further information: James Smith, (416) 815-0700 x 229,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890